Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/3503821

Documents

In Collections

This item can be found in the following collections:

Boele, F.W.; Otter, P.W.M. den; Reijneveld, J.C.; Hamer, P.C.D.; Thuijl, H.F. van; Lorenz, L.M.C.; ... ; Klein, M. (2022)

Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: a longitudinal study spanning two decades

Article / Letter to editor
Background: While patients with diffuse low-grade glioma (LGG) often survive for years, there is a risk of tumor progression which may impact patients' long-term health-related quality of life (HRQOL) and neurocognitive functioning (NCF). We present a follow-up of LGG patients and their informal caregivers (T3) who took part in our previous HRQOL investigations (T1, M = 7 and T2 M = 13 years after diagnosis). Methods: Participants completed HRQOL (short form-36 health survey [SF-36]; EORTC-BN20), fatigue (Checklist Individual Strength [CIS]), and depression (Center for Epidemiological Studies-Depression [CES-D]) questionnaires and underwent NCF assessments. T3 scores were compared with matched controls. Changes over time (T1-T2-T3) on group and participant level were assessed. Where available, histology of the initial tumor was revised and immunohistochemical staining for IDH1 R132H mutant protein was performed. Results: Thirty patients and nineteen caregivers participated. Of N ...Show moreBackground: While patients with diffuse low-grade glioma (LGG) often survive for years, there is a risk of tumor progression which may impact patients' long-term health-related quality of life (HRQOL) and neurocognitive functioning (NCF). We present a follow-up of LGG patients and their informal caregivers (T3) who took part in our previous HRQOL investigations (T1, M = 7 and T2 M = 13 years after diagnosis). Methods: Participants completed HRQOL (short form-36 health survey [SF-36]; EORTC-BN20), fatigue (Checklist Individual Strength [CIS]), and depression (Center for Epidemiological Studies-Depression [CES-D]) questionnaires and underwent NCF assessments. T3 scores were compared with matched controls. Changes over time (T1-T2-T3) on group and participant level were assessed. Where available, histology of the initial tumor was revised and immunohistochemical staining for IDH1 R132H mutant protein was performed. Results: Thirty patients and nineteen caregivers participated. Of N = 11 with tissue available, 3 patients had confirmed diffuse LGG. At T3, patients (M = 26 years after diagnosis) had HRQOL and NCF similar to, or better than controls, yet 23.3% and 53.3% scored above the cut-off for depression (>= 16 CES-D) and fatigue (>= 35 CIS), respectively. Caregivers' HRQOL was similar to controls but reported high rates of fatigue (63.2%). Over time, patients' mental health improved (P < .05). Minimal detectable change in HRQOL over time was observed in individual patients (30% improvement; 23.3% decline; 20% both improvement and decline) with 23.3% remaining stable. NCF remained stable or improved in 82.8% of patients. Conclusions: While HRQOL and NCF do not appear greatly impacted during long-term survivorship in LGG, depressive symptoms and fatigue are persistent.Show less
depression
fatigue
low-grade glioma
quality of life
survivorship
All authors
Boele, F.W.; Otter, P.W.M. den; Reijneveld, J.C.; Hamer, P.C.D.; Thuijl, H.F. van; Lorenz, L.M.C.; Wesseling, P.; Lagerwaard, F.J.; Taphoorn, M.J.B.; Kouwenhoven, M.C.M.; Snijders, T.J.; Douw, L.; Klein, M.
Date
2022-08-01
Journal
Neuro-Oncology
Volume
25
Issue
2
Pages
351 - 364
DOI
doi:10.1093/neuonc/noac185